{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:18:34Z","timestamp":1783401514517,"version":"3.54.6"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The management of cancer patients follows a Diagnostic Therapeutic and Care Pathway (PDTA) approach, aimed at achieving the optimal balance between care and quality of life. To support this process, precision medicine and innovative technologies [e.g., next-generation sequencing (NGS)] allow rapid identification of genetic-molecular alterations useful for the design of PDTA-approved therapies. If the standard approach proves inadequate, the Molecular Tumor Board (MTB), a group comprising specialists from diverse disciplines, can step in to evaluate a broader molecular profile, proposing potential therapies beyond evidence levels I\u2013II or considering enrolment in clinical trials. Our aim is to analyze the role of the MTB in the entire management of patients in our institute and its impact on the strategy of personalized medicine, particularly when all approved treatments have failed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>In alignment with European and national guidelines, a panel of clinicians and preclinical specialists from our institution was defined as the MTB core team. We designed and approved a procedure for the operation of this multidisciplinary group, which is the only one operating in the Puglia region.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results and discussion<\/jats:title><jats:p>In 29\u2009months (2021\u20132023), we discussed and analyzed 93 patients. A total of 44% presented pathogenic alterations, of which 40.4% were potentially actionable. Only 11 patients were proposed for enrollment in clinical trials, treatment with off-label drugs, or AIFA (the Italian pharmaceutical agency for drugs)\u20145% funding. Our process indicators, time to analysis, and number of patient cases discussed are in line with the median data of other European institutions. Such findings underscore both the importance and usefulness of the integration of an MTB process into the care of oncology patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1432628","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T04:16:42Z","timestamp":1726028202000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["The molecular tumor board as a step in cancer patient management: a southern Italian experience"],"prefix":"10.3389","volume":"11","author":[{"given":"Stefania","family":"Tommasi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonarda","family":"Maurmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Carella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girolamo","family":"Ranieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"De Summa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Mannavola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo Emanuele","family":"Chiur\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Guida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Nisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Montrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Giotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Patruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Lacalamita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brunella","family":"Pilato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Alfredo","family":"Zito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Fucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio Antonio","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Ditonno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Nardulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Quaresmini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabino","family":"Strippoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ejca.2023.03.041","article-title":"Do more targets allow more cancer treatments, or not?","volume":"187","author":"Marchetti","year":"2023","journal-title":"Eur J Cancer"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e2100349","DOI":"10.1200\/PO.21.00349","article-title":"Clinical utility of genomic testing in cancer care","volume":"6","author":"Pritchard","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"ref3","article-title":"Italian Ministry of Health. Decreto Ministeriale n. 70 2 Aprile 2015","year":"2015"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"7355","DOI":"10.2147\/OTT.S99807","article-title":"Next-generation sequencing: advances and applications in cancer diagnosis","volume":"9","author":"Serrat\u00ec","year":"2016","journal-title":"Onco Targets Ther"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO precision medicine working group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"4965","DOI":"10.1038\/s41467-020-18613-3","article-title":"Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-one strategy","volume":"11","author":"Kato","year":"2020","journal-title":"Nat Commun"},{"key":"ref7","article-title":"Puglia Region Delibera 63 del 31.01.24 Three-year integrated plan of activities and organization 2024\u20132026 (PIAO)","year":""},{"key":"ref8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3389\/fonc.2020.00085","article-title":"The multidisciplinary team (MDT) approach and quality of care","volume":"10","author":"Taberna","year":"2020","journal-title":"Front Oncol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1016\/j.ejca.2006.03.034","article-title":"The multidisciplinary meeting: an indispensable aid to communication between different specialties","volume":"42","author":"Ruhstaller","year":"2006","journal-title":"Eur J Cancer"},{"key":"ref10","year":""},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e324","DOI":"10.1093\/oncolo\/oyad020","article-title":"Implementation of precision oncology in clinical practice: results of a National Survey for health care professionals","volume":"28","author":"Fasola","year":"2023","journal-title":"Oncologist"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","article-title":"Complex heatmaps reveal patterns and correlations in multidimensional genomic data","volume":"32","author":"Gu","year":"2016","journal-title":"Bioinformatics"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"6666","DOI":"10.3390\/jcm12206666","article-title":"Molecular tumour board (MTB): from standard therapy to precision medicine","volume":"12","author":"Ballatore","year":"2023","journal-title":"J Clin Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ejca.2023.01.019","article-title":"Molecular tumour board at European Institute of Oncology: report of the first three year activity of an Italian precision oncology experience","volume":"183","author":"Repetto","year":"2023","journal-title":"Eur J Cancer"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"4632","DOI":"10.1111\/cas.15993","article-title":"Prognostic impact of cancer genomic profile testing for advanced or metastatic solid tumors in clinical practice","volume":"114","author":"Fukada","year":"2023","journal-title":"Cancer Sci"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.trecan.2020.05.008","article-title":"Molecular tumor boards in clinical practice","volume":"6","author":"Luchini","year":"2020","journal-title":"Trends Cancer"},{"key":"ref17","first-page":"1","article-title":"Documento di consenso sullo sviluppo e sull\u2019organizzazione dell\u2019oncologia mutazionale in Italia. Il Pensiero Scientifico Editore","volume":"21","author":"Martini","year":"2020","journal-title":"Suppl A Politiche Sanit"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.3390\/cells12222632","article-title":"Genomic profiling and clinical outcomes of targeted therapies in adult patients with soft tissue sarcomas","volume":"12","author":"Kokkali","year":"2023","journal-title":"Cells"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s11864-018-0589-y","article-title":"Is there value in molecular profiling of soft-tissue sarcoma?","volume":"19","author":"Italiano","year":"2018","journal-title":"Curr Treat Options Oncol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1634\/theoncologist.2017-0290","article-title":"Next-generation sequencing for patients with sarcoma: a single center experience","volume":"23","author":"Cote","year":"2018","journal-title":"Oncologist"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1001\/jamaoncol.2018.0723","article-title":"Targetable alterations in adult patients with soft-tissue sarcomas: insights for personalized therapy","volume":"4","author":"Lucchesi","year":"2018","journal-title":"JAMA Oncol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1158\/2159-8290.CD-23-0605","article-title":"Targeting MDM2 in soft-tissue sarcomas (and other solid tumors): the revival?","volume":"13","author":"Italiano","year":"2023","journal-title":"Cancer Discov"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"103029","DOI":"10.1016\/j.critrevonc.2020.103029","article-title":"Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: a comprehensive review","volume":"153","author":"Assi","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s13046-022-02512-0","article-title":"Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of alliance against cancer","volume":"41","author":"Ciliberto","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e2200030","DOI":"10.1200\/GO.22.00030","article-title":"Impact of molecular tumor board on the clinical Management of Patients with Cancer","volume":"8","author":"Behel","year":"2022","journal-title":"JCO Glob Oncol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"100775","DOI":"10.1016\/j.lanwpc.2023.100775","article-title":"The impact of the multi-disciplinary molecular tumour board and integrative next generation sequencing on clinical outcomes in advanced solid tumours","volume":"36","author":"El Helali","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.3390\/cancers15061727","article-title":"Role of the molecular tumor board for the personalized treatment of patients with metastatic breast cancer: a focus on the state of the art in Italy","volume":"15","author":"Irelli","year":"2023","journal-title":"Cancers"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1186\/s12885-024-12338-y","article-title":"Pragmatic nationwide master observational trial based on genomic alterations in advanced solid tumors: KOrean precision medicine networking group study of MOlecular profiling guided therapy based on genomic alterations in advanced solid tumors (KOSMOS)-II study protocol KCSG AL-22-09","volume":"24","author":"Kim","year":"2024","journal-title":"BMC Cancer"}],"updated-by":[{"DOI":"10.3389\/fmed.2024.1511339","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000}}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1432628\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T11:12:51Z","timestamp":1729854771000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1432628\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":28,"alternative-id":["10.3389\/fmed.2024.1432628"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1432628","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fmed.2024.1511339","asserted-by":"object"}]},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,11]]},"article-number":"1432628"}}